United States - English - NLM (National Library of Medicine)

phoenix pharmaceutical, inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - neomycin sulfate 3.5 mg in 1 ml - for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common bacterial eye pathogens: staphylococcus aureus, escherichia coli, haemophilus influenzae, klebsiella/enterobacter sp

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - neomycin 3.5 mg in 1 ml - for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. ocular corticosteroids are indicated in inflammatory conditions of the papebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common bacterial eye pathogens: staphylococcus aureus, escherichia coli, haemophilus influenzae, klebsiella/enterob

United States - English - NLM (National Library of Medicine)

phoenix pharmaceutical, inc. - dexamethasone sodium phosphate (unii: ai9376y64p) (dexamethasone - unii:7s5i7g3jql) - for the treatment of the following conditions: ophthalmic: steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. otic: steroid responsive inflammatory conditions of the external auditory meatus, such as allergic otitis externa, selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. epithelial herpes simplex keratitis (dendritic keratitis). acute infectious stages of vaccinia, varicella and many other viral diseases of the cornea and conjunctiva. mycobacterial infection of the eye. funga

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql), neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k) - for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or risk of bacterial ocular infection exists. ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitises is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drugs in this product is active against the following common bacterial eye pathogens: staphylococcus aureus , escherichia coli, haemophilus influenzae , klebsi

United States - English - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common bacterial eye pathogens: staphylococcus aureus, escherichia coli , haemophilus influenzae, klebsiella/enter

United States - English - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - sulfacetamide sodium and prednisolone sodium phosphate ophthalmic solution is indicated for corticosteroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active

United States - English - NLM (National Library of Medicine)

eyepoint pharmaceuticals, inc - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - yutiq ® (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. yutiq is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases. yutiq is contraindicated in patients with known hypersensitivity to any components of this product. risk summary adequate and well-controlled studies with yutiq have not been conducted in pregnant women to inform drug associated risk. animal reproduction studies have not been conducted with yutiq. it is not known whether yutiq can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. yutiq should be given to a pregnant woman only if the potential benefit justifies the potential risk to the fetus. all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the united states general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary systemically administered corticosteroids are present in human milk and can suppress growth, interfere with endogenous corticosteroid production. clinical or nonclinical lactation studies have not been conducted with yutiq. it is not known whether intravitreal treatment with yutiq could result in sufficient systemic absorption to produce detectable quantities of fluocinolone acetonide in human milk, or affect breastfed infants or milk production. the developmental and health benefits of breastfeeding should be considered, along with the mother's clinical need for yutiq and any potential adverse effects on the breastfed child from yutiq. safety and effectiveness of yutiq in pediatric patients have not been established. no overall differences in safety or effectiveness have been observed between elderly and younger patients.

Israel - English - Ministry of Health

pharma medis - ketamine as hydrochloride - solution for injection / infusion - ketamine as hydrochloride 50 mg/ml - ketamine - as the sole anaesthetic agent for diagnostic and surgical procedures. when used by intravenous or intramuscular injection, ketamine-hameln is best suited for short procedures. with additional doses, or by intravenous infusion, ketamine-hameln can be used for longer procedures. if skeletal muscle relaxation is desired, a muscle relaxant should be used and respiration should be supported.for the induction of anesthesia prior to the administration of other general anesthetic agents.to supplement other anesthetic agents.specific areas of application or types of procedures:when the intramuscular route of administration is preferred.debridement, painful dressings, and skin grafting in burned patients, as well as other superficial surgical procedures.neurodiagnostic procedures such as pneumoencephalograms, ventriculograms, myelograms, and lumbar punctures.diagnostic and operative procedures of the eye, ear, nose, and mouth, including dental extractions.note: eye movements may persist during ophthalmological procedures. anaesthesia in poor-risk patients with depression of vital functions or where depression of vital functions must be avoided, if at all possible. orthopaedic procedures such as closed reductions, manipulations, femoral pinning, amputations, and biopsies. sigmoidoscopy and minor surgery of the anus and rectum, circumcision and pilonidal sinus. cardiac catheterization procedures.caesarian section; as an induction agent in the absence of elevated blood pressure. anaesthesia in the asthmatic patient, either to minimise the risks of an attack of bronchospasm developing, or in the presence of bronchospasm where anaesthesia cannot be delayed.

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common bacterial eye pathogens: staphylococcus aureus, escherichia coli, haemophilus influenzae, klebsiella/enteroba

United States - English - NLM (National Library of Medicine)

trifecta pharmaceuticals usa llc - polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), bacitracin zinc (unii: 89y4m234es) (bacitracin - unii:58h6rwo52i) - first aid antibiotic first aid antibiotic first aid antibiotic first aid to help prevent infection in minor: - cuts - scrapes - burns deep or puncture wounds animal bites serious burns - in eyes - over large areas of the body - if you are allergic to any of the ingredients - if you need to use longer than 1 week - the condition persists or gets worse - a rash or allergic reaction develops